Related Experiment Videos
Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats
M Higa1, Y T Zhou, M Ravazzola
1Gifford Laboratories, Center for Diabetes Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235, USA.
Abstract:
To determine whether the antidiabetic action of troglitazone (TGZ), heretofore attributed to insulin sensitization, also involves protection of beta cells from lipoapoptosis, we treated prediabetic Zucker Diabetic Fatty rats with 200 mg/kg per day of TGZ. Their plasma-free fatty acids and triacylglycerol fell to 1.3 mM and 111 mg/dl, respectively, compared with 2.0 mM and 560 mg/dl in untreated controls. Their islet triacylglycerol content was 34% below controls. In islets of control rats, beta cells were reduced by 82% and the islet architecture was disrupted; beta-cell glucose transporter-2 was absent, 85% of their mitochondria were altered, and they were unresponsive to glucose. In treated rats, the loss of beta cells was prevented, as were the loss of beta cell glucose transporter-2, the mitochondrial alterations, and the impairment of glucose-stimulated insulin secretion. We conclude that the antidiabetic effect of TGZ in prediabetic Zucker Diabetic Fatty rats involves prevention of lipotoxicity and lipoapoptosis of beta cells, as well as improvement in insulin sensitivity.
Insights
Troglitazone (TGZ) protects prediabetic rats from beta cell death caused by fat buildup. This drug improves insulin sensitivity and preserves pancreatic beta cell function, offering a dual antidiabetic mechanism.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Troglitazone (TGZ) is known for improving insulin sensitivity.
- Its role in protecting pancreatic beta cells from lipoapoptosis requires further investigation.
Purpose of the Study:
- To investigate if troglitazone (TGZ) protects against beta cell lipoapoptosis in prediabetic rats.
- To determine if TGZ's antidiabetic effects extend beyond insulin sensitization.
Main Methods:
- Prediabetic Zucker Diabetic Fatty rats were treated with TGZ (200 mg/kg/day).
- Plasma free fatty acids, triacylglycerol, and islet triacylglycerol levels were measured.
- Islet architecture, beta cell mass, glucose transporter-2, mitochondrial integrity, and glucose-stimulated insulin secretion were assessed.
Main Results:
- TGZ treatment significantly reduced plasma and islet triacylglycerol levels.
- TGZ prevented the 82% reduction in beta cells observed in control rats.
- TGZ preserved beta cell glucose transporter-2, mitochondrial function, and glucose-stimulated insulin secretion.
Conclusions:
- Troglitazone (TGZ) exhibits antidiabetic effects by preventing beta cell lipotoxicity and lipoapoptosis.
- TGZ improves insulin sensitivity and protects pancreatic beta cells in prediabetic Zucker Diabetic Fatty rats.